Clinical trials: Anti-coagulation Therapy
AKI - Acute Kidney Injury, CKD 5D, Hemodialysis
Personalized Two-stage Regional Citrate Anticoagulation for CRRT in Patients With Citrate Metabolism Impairment
The purpose of this study is to compare the efficacy and safety of an individualized two-stage calcium supplementation method versus a conventional commercial RCA-CRRT module in RCA-CRRT for patients with citrate metabolism…
- Conditions
- AKI - Acute Kidney Injury, CKD 5D, Hemodialysis, Hepatic Failure
- Trial name
- PRECISE (NCT07579663)
- Testing
- Two-stage calcium supplementation in RCA-CRRT, Commercial RCA-CRRT module
- Volunteers
- 142 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Anticoagulation, Coronary Endarterectomy
Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
Coronary endarterectomy (CE) combined with coronary artery bypass grafting (CABG) can be the final option for achieving complete revascularization in diffuse coronary artery disease patients.
- Trial name
- NCT05782270
- Testing
- Warfarin, DAPT, CE+CABG
- Where
- China
- Volunteers
- 202 people
- Sponsor
- China National Center for Cardiovascular Diseases
Stroke, Acute, Atrial Fibrillation
SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF)
The purpose of this study is to determine choice of anticoagulant therapy during acute and chronic stages of ischemic stroke/TIA and short- and long-term outcomes, including stroke recurrence and bleeding complications, in…
- Trial name
- SAMURAI-NVAF (NCT01581502)
- Testing
- This is an observational study.
- Where
- 16 sites in Japan
- Volunteers
- 1,000 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Deep Vein Thrombosis, Venous Thrombosis
Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy
Following the findings of the clinical trials in drug development, this global non-interventional cohort field study will investigate rivaroxaban under clinical practice conditions in comparison with current standard of care for…
- Trial name
- XALIA (NCT01619007)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care
- Where
- 21 sites in Austria, Belgium and 19 more
- Volunteers
- 5,145 people
- Sponsor
- Bayer
Atrial Fibrillation
Finnish AntiCoagulation in Atrial Fibrillation (FinACAF)
The aim of FINACAF study is to evaluate the incidence and risk of stroke, systemic thromboembolic events, myocardial infarction, major bleeding events, and mortality in relation to different attitudes regarding stroke prevention…
- Trial name
- FinACAF (NCT04645537)
- Volunteers
- 400,000 people
- Sponsor
- Helsinki University Central Hospital
Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
This trial will study different dose levels of hA20 (IMMU-106) to see if they are safe and effective for treating ITP.
- Conditions
- Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Autoimmune
- Trial name
- NCT00547066
- Testing
- veltuzumab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
Atrial Fibrillation, Atrial Flutter
Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk
The IMPACT Study will investigate the potential clinical benefit of the combined use of BIOTRONIK Home Monitoring (HM) technology and a predefined anticoagulation plan compared to conventional device evaluation and…
- Conditions
- Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial
- Trial name
- IMPACT (NCT00559988)
- Testing
- Home Monitoring Guided OAC, Physician-Directed OAC
- Where
- 80 sites in United States, Australia and 4 more
- Volunteers
- 2,718 people
- Sponsor
- Biotronik, Inc.
Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication
Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO
The SURVIVE trial aims to test whether using an anti-thrombotic regimen involving cangrelor can reduce bleeding risk while maintaining effective antithrombotic effects in patients on VA-ECMO due to cardiogenic shock (CS)/ cardiac…
- Conditions
- Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication, Platelet Dysfunction
- Trial name
- SURVIVE (NCT06792643)
- Testing
- Cangrelor
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
Thromboembolism, Bleeding
Anticoagulant After Implantation of Biological Aortic Valve Comparing With Aspirin
The optimal medical strategy for prevention of thromboembolic events after bioprosthetic aorta valve replacement (BAVR) remains controversial.
- Trial name
- NCT01452568
- Testing
- Aspirin, Warfarin
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Atrial Fibrillation, Stroke
Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing
The purpose of this study is to compare the effectiveness of prescribing oral anticoagulation therapy by pharmacist intervention compared to enhanced usual care in participants with unrecognized AF and/or known AF but not taking…
- Trial name
- PIAAFRx (NCT03126214)
- Testing
- Anticoagulants
- Where
- Canada
- Volunteers
- 79 people
- Sponsor
- University of Alberta
Immune Thrombocytopenia, Treatment
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
This single-arm, open-label phase II study aim to evaluate the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) combined with Rituximab in ITP patients.This study will be conducted in ITP patients who had not…
- Trial name
- NCT07362199
- Testing
- Rituximab combined with Daratumumab（Anti-CD38 Monoclonal Antibody）
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
COVID 19 Associated Coagulopathy
Covid-19 Associated Coagulopathy
This prospective, randomized, open-label, multi-center interventional study is designed to compare the safety and efficacy of two LMWH dosing protocols in patients admitted to the University of Iowa Hospitals with COVID-19 who…
- Trial name
- NCT04360824
- Testing
- Intermediate dose thromboprophylaxis, Standard of Care thromboprophylaxis
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- University of Iowa
Pulmonary Embolism
Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism
Currently there is no clear guidance for the treatment of moderate risk of pulmonary embolism. The aim of the study is to compare two different therapeutic modalities - standard anticoagulation versus thrombolytic treatment…
- Trial name
- CONTACT-SPE (NCT02132689)
- Testing
- Actilyse (Thrombolytic therapy), Heparine (Standard anticoagulation therapy)
- Where
- 2 sites in Czechia
- Volunteers
- 100 people
- Sponsor
- University Hospital Ostrava
Pulmonary Embolism, Pulmonary Hypertension
Ventilation and Perfusion Scan in Pulmonary Embolism Following Catheter Directed Thrombectomy Versus Anticoagulation Alone
Clinical presentation of acute pulmonary embolism (PE) is complex and varied and not uncommonly involves respiratory failure with dyspnea or hypoxia.
- Conditions
- Pulmonary Embolism, Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- VQPE (NCT05133713)
- Testing
- Catheter directed therapy, Systemic anticoagulation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Arizona
Stroke, Atrial Fibrillation (AF)
Early Anticoagulation Therapy After Endovascular Treatment for Acute Ischemic Stroke With Atrial Fibrillation
The goal of this clinical trial is to learn whether starting a direct oral anticoagulant (DOAC) early after endovascular treatment works to improve outcomes in patients with ischemic stroke related to atrial fibrillation.
- Trial name
- EATAF (NCT07849777)
- Testing
- Early Initiation of DOAC Therapy, Antiplatelet Bridging Followed by DOAC Therapy
- Where
- 2 sites in China
- Volunteers
- 474 people
- Sponsor
- The Fourth Affiliated Hospital of Soochow University
Left Atrial Appendage Closure, Thrombosis
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
The objective of the study is to compare short-term (8 weeks) anticoagulation therapy (DOAC) vs. antiplatelet therapy for the prevention of device thrombosis following transcatheter LAAC.
- Conditions
- Left Atrial Appendage Closure, Thrombosis, Stroke, TIA
- Trial name
- ANDES (NCT03568890)
- Testing
- Rivaroxaban, dabigatran, apixaban, or edoxaban, Clopidogrel -75 mg/day, Low dose aspirin -80 to 125 mg/day-
- Where
- Canada
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Anticoagulants, Platelet Aggregation Inhibitors
WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)
The study will assess the hypothesis that the combination warfarin \& clopidogrel 75 mg/day is superior to triple therapy (warfarin + clopidogrel 75mg/day + aspirin 80mg/day) with respect to bleeding complications while equally…
- Conditions
- Anticoagulants, Platelet Aggregation Inhibitors, Stents, Atrial Fibrillation
- Trial name
- WOEST (NCT00769938)
- Testing
- PCI (percutaneous coronary intervention)
- Where
- 15 sites in Belgium, Netherlands
- Volunteers
- 573 people, healthy volunteers welcome
- Sponsor
- R&D Cardiologie
Atrial Fibrillation
The Effect and Safety of Different Intensity Anticoagulation Therapy in Elderly Patients With Non-valvular Atrial Fibrillation
Current guidelines recommend standard warfarin anticoagulation international normalized ratio (INR) goal of 2.0-3.0 in adults with non valvular atrial fibrillation (NVAF).
- Trial name
- NCT01438580
- Testing
- Warfarin, aspirin
- Where
- China
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Nanjing Medical University
Drug Therapy Management
Medication Review Focusing on Anticoagulation Therapy in Swiss Community Pharmacies
Oral anticoagulation therapy (OAC) entails a high potential for adverse events and strict adherence is needed.Thus, medication review and identification of safety issues and knowledge gaps about OAC is critically important.
- Trial name
- NCT02703727
- Testing
- Extended polymedication check
- Where
- Switzerland
- Volunteers
- 90 people
- Sponsor
- University Hospital, Basel, Switzerland
Pulmonary Embolism
Duration of Therapeutic Anticoagulation in Patients With Pulmonary Embolism
Current management of intermediate- and high-risk pulmonary embolism is primarily based on curative subcutaneous or intravenous anticoagulation, with or without systemic fibrinolytic therapy or thrombectomy.
- Trial name
- ACEP (NCT06912009)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France